RecruitingNCT06524843

Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma

Generation of Synthetic Patient Data (RAW) for Risk Evaluation of Bone Metastases Derived From Carcinoma


Sponsor

Costantino Errani

Enrollment

250 participants

Start Date

Sep 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01/01/2010 to 31/12/2022. A review will be made from the medical records, radiological imaging, and histological data of these patients


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥ 18 years
  • Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases
  • Availability of imaging and clinical data
  • Availability of at least one follow-up during the last 12 months form diagnosis

Exclusion Criteria1

  • At least one inclusion creteria not met

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAnalysis

Analysis and review of imaging and clinical data


Locations(1)

IRCCS Istituto Ortopedico Rizzoli

Bologna, Emilia-Romagna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06524843


Related Trials